6869.T Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 09:15):

Stats
Šios dienos apimtis	1.10M
Vidutinė apimtis	1.66M
Rinkos kapitalizacija	1 550.87B
EPS	¥0 ( 2024-02-08 )
Kita pelno data	( ¥25.37 ) 2024-05-08
Last Dividend	¥2.00 ( 2023-03-30 )
Next Dividend	¥0 ( N/A )
P/E	34.60
ATR14	¥1.939 (0.08%)

Tūris Koreliacija

Ilgas: -0.27 (neutral)

Trumpas: 0.57 (weak)

Signal:(55.758) Neutral

Sysmex Corporation Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Sysmex Corporation Koreliacija - Valiuta/Žaliavos

-0.36
( neutral )

-0.48
( neutral )

0.08
( neutral )

-0.18
( neutral )

-0.57
( weak negative )

0.03
( neutral )

Sysmex Corporation Finansinės ataskaitos

Annual	2022
Pajamos:	¥410.50B
Bruto pelnas:	¥216.08B (52.64 %)
EPS:	¥72.94

FY	2022
Pajamos:	¥410.50B
Bruto pelnas:	¥216.08B (52.64 %)
EPS:	¥72.94

FY	2022
Pajamos:	¥363.78B
Bruto pelnas:	¥190.59B (52.39 %)
EPS:	¥210.88

FY	2021
Pajamos:	¥305.07B
Bruto pelnas:	¥154.30B (50.58 %)
EPS:	¥158.65

Financial Reports:

No articles found.

Sysmex Corporation Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
¥40.00 (N/A)	¥0 (N/A)	¥2.00 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)

Sysmex Corporation Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 6.53 - Stable (30.68%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	¥1.500	2001-03-27
Last Dividend	¥2.00	2023-03-30
Next Dividend	¥0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	46	--
Total Paid Out	¥628.25	--
Avg. Dividend % Per Year	0.00%	--
Score	4.35	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	6.53
Div. Directional Score	9.65	--

Next Divdend (Est)
(2024-07-03)

¥0 Estimate 1.26 %

Dividend Stability

0.10 Bad

Dividend Score

4.35

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for JPX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
8255.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
7616.T	Ex Dividend Junior	2024-03-28	Annually	0.00%
6817.T	Ex Dividend Knight	2023-12-28	Semi-Annually	0.00%
6171.T	Ex Dividend Knight	2023-12-28	Semi-Annually	0.00%
4912.T	Ex Dividend Knight	2023-12-28	Semi-Annually	0.00%
4072.T	Ex Dividend Knight	2023-12-28	Semi-Annually	0.00%
3288.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
2335.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
9278.T	Ex Dividend Junior	2024-05-30	Annually	0.00%
8020.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.103	1.500	7.94	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0794	1.200	7.35	8.82	[0 - 0.3]
returnOnEquityTTM	0.112	1.500	9.87	10.00	[0.1 - 1]
payoutRatioTTM	0.390	-1.000	6.10	-6.10	[0 - 1]
currentRatioTTM	3.10	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	1.972	0.800	3.11	2.49	[0.8 - 2.5]
cashRatioTTM	0.603	1.500	7.76	10.00	[0.2 - 2]
debtRatioTTM	0.0882	-1.500	8.53	-10.00	[0 - 0.6]
interestCoverageTTM	37.92	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	108.38	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	28.58	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.123	-1.500	9.51	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.532	1.000	4.47	4.47	[0.2 - 0.8]
operatingProfitMarginTTM	0.168	1.000	8.65	8.65	[0.1 - 0.6]
cashFlowToDebtRatioTTM	1.355	1.000	3.58	3.58	[0.2 - 2]
assetTurnoverTTM	0.773	0.800	8.18	6.55	[0.5 - 2]
Total Score				12.77

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	34.55	1.000	6.61	0	[1 - 100]
returnOnEquityTTM	0.112	2.50	9.92	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	28.58	2.00	0.474	10.00	[0 - 30]
dividendYielPercentageTTM	2.25	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	108.38	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0.390	1.500	6.10	-6.10	[0 - 1]
pegRatioTTM	0.907	1.500	7.28	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.155	1.000	8.63	0	[0.1 - 0.5]
Total Score				6.53

Sysmex Corporation

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. The company offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. It also provides urine formed sediment analysis systems; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS. In addition, the company offers cancer lymph node metastasis testing systems to detect information to help in diagnosing lymph node metastasis; cancer genome profiling systems; and cytogenic testing and lab assay services. It is also involved in the development and sale of software for diagnostic information systems; provision of facility management, office, and welfare services; development, manufacture, and sale of nucleic acid analogs; development, operation, and maintenance of IT solutions, platforms, and applications related to digital medicine; marketing, development, design, manufacture, sale, and after-sales service related to medical robots; and distribution and after sales support of medical devices and reagents for biotechnology, medical technology, and molecular cell analysis. The company serves national and other public hospitals, private hospitals, universities, research institutes, other medical institutions, etc. It also exports its products to approximately 190 countries. Sysmex Corporation has a strategic alliance with QIAGEN N.V. for the development and commercialization of cancer companion diagnostics using Plasma-Safe-SeqS technology. The company was formerly known as TOA Medical Electronics Co., Ltd. and changed its name to Sysmex Corporation in October 1998. Sysmex Corporation was founded in 1968 and is headquartered in Kobe, Japan.